Optain Health

Chadstone, Australia  All Australia companies → Founded 2023
Imaging AI Specialist Specialty-Focused AI
Series A — $38 million

Products

Optain Platform (Resolve + Optain Grading)
Optain Health
Clinical Decision Support & Reference
The Optain Platform combines an FDA-cleared robotic camera with AI-powered grading to enable early detection of diabetic retinopathy, suspect glaucoma, and age-related macular degeneration in primary care and other non-ophthalmic settings.

See all 1 product →

About Optain Health

Optain Health is a healthcare technology company that leverages artificial intelligence (AI), robotic retinal imaging, and teleophthalmology to facilitate earlier detection of both ocular and systemic diseases. The company’s core offering is its Oculomics platform, which utilizes a portable robotic camera to capture high-resolution retinal images rapidly and without the need for pupil dilation. Integrated AI workflows then analyze these images to identify various sight-threatening eye conditions and assess cardiovascular disease risk.

For physicians, Optain’s platform provides a non-invasive clinical support tool designed to democratize access to specialized disease screening, improve diagnostic speed, and minimize missed diagnoses. The system delivers real-time AI diagnostics, often in under 60 seconds with high accuracy, enabling point-of-care diagnosis and seamless integration into existing clinic workflows. This approach aims to enhance screening adherence, particularly in underserved communities, and supports recurring revenue for providers through reimbursable CPT codes for annual screenings and preventive services.

Optain’s technology is built upon over a decade of research, primarily led by Professor Mingguang He in Australia, and is designed to expand access to oculomics into primary care, optometry, and other non-specialist settings, with minimal disruption to clinical staffing or workflows. The company’s mission is to provide faster, easier, and more equitable disease screening globally.

Focus Areas

Retinal imaging AI teleophthalmology early disease detection diabetic retinopathy glaucoma age-related macular degeneration (AMD) cardiovascular disease risk systemic diseases oculomics

Business Intelligence

Key InvestorsInsight Partners, Memorial Hermann Health System, Northwell Health, Novant Health, The Ohio State University Wexner Medical Center, UPMC, Informed Ventures, Lumio Capital, Meridian Ventures, UniQuest Extension Fund, Aegis Ventures, Northwell Holdings
PartnershipsAegis Digital Consortium (collaboration of 11 leading regional US health systems), Memorial Hermann Health System, Northwell Health, Novant Health, The Ohio State University Wexner Medical Center, UPMC
AcquisitionsEyePACS
TechnologyAI-powered oculomics, robotic retinal imaging, portable robotic camera, integrated AI workflows, teleophthalmology, cloud connectivity, AI-enabled Software as a Medical Device (SaMD)
FDA Clearances1 cleared products (estimated)

What Physicians Need to Know

Retinal Imaging
Optain Health specializes in non-invasive, high-quality retinal imaging using a portable robotic fundus camera that captures images rapidly without requiring pupil dilation. This technology is designed for true point-of-care use, making it easy for clinicians to master in minutes.
AI & Early Disease Detection
Their core expertise lies in AI-powered oculomics, utilizing advanced algorithms to analyze full-color retinal images. This enables early and accurate detection of sight-threatening eye diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD), with an accuracy rate of 95%.
Teleophthalmology
Optain has expanded its reach in teleophthalmology through the acquisition of EyePACS, the largest teleophthalmology network in the U.S. This integration aims to broaden access to retinal screening in primary care settings and community clinics.
Systemic Disease Risk (Oculomics)
Leveraging oculomics, the science of using the eye as a 'window to the body,' Optain's platform can also assess cardiovascular disease risk and has future potential for detecting other systemic conditions like kidney disease and neurological conditions from retinal images.
Physician Tip

Optain Health's platform offers physicians a rapid, accurate, and non-invasive tool for early disease detection, improving diagnostic speed and minimizing missed diagnoses. The portable, automated camera and AI-driven analysis streamline workflows, enabling point-of-care screening without the need for specialist training or pupil dilation. This facilitates earlier intervention, leading to better patient outcomes and potentially reducing long-term healthcare costs. Furthermore, the system supports recurring revenue through reimbursable CPT codes for annual screenings and preventive services, and provides evidence-based reports for informed decision-making. The integration with teleophthalmology networks expands access to specialized screening, particularly in primary care and underserved communities.

Optain's Eyetelligence Assure Software as a Medical Device (SaMD) and Portable Automatic Fundus Camera Turnkey Solution are designed for easy integration into any clinic, eliminating complex setups. The platform offers seamless cloud connectivity for image access and sharing, and the combined platform with EyePACS aims for integration with all major U.S. EHR systems to support population health programs.

Products by Optain Health

1 product in the directory

Optain Platform (Resolve + Optain Grading)
Optain Health
Clinical Decision Support & Reference
The Optain Platform combines an FDA-cleared robotic camera with AI-powered grading to enable early detection of diabetic retinopathy, suspect glaucoma, and age-related macular degeneration in primary care and other non-ophthalmic settings.

Reviews & Opinions

No web reviews on file yet for Optain Health. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Optain Health.

Loading videos...

Videos load interactively. If none appear, search YouTube for Optain Health →

View all on YouTube

Press & Coverage

Fierce Healthcare
Startup Optain Health acquires EyePACS to expand retinal screening in primary care
Optain Health, a startup utilizing AI-powered retinal screening technology, acquired EyePACS to integrate its teleophthalmology network and broaden access to eye disease screening in primary care. This acquisition aims to prevent avoidable blindness and improve patient care through earlier disease detection.
2025-11
Ophthalmology Times
Optain Health secures $26 million Series A funding | Eye Care Network - Ophthalmology Times
Optain Health closed an oversubscribed $26 million Series A funding round, led by Insight Partners, to expand its AI-driven retinal imaging technology, Oculomics, globally. The funding will support enterprise deployments and market expansion for their non-invasive test that detects eye diseases and assesses cardiovascular risk.
2025-09
HLTH
Optain Health Raises $26M to Scale AI-Powered Retinal Screening Platform - HLTH
Optain Health secured $26 million in Series A funding to accelerate the deployment of its AI-powered retinal screening technology across the U.S. This round included strategic investments from seven major health systems, aiming to enhance screening accessibility and improve patient outcomes.
2025-09
PR Newswire
Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond
Optain Health announced the close of an oversubscribed $26 million Series A funding round, led by Insight Partners, with participation from existing investors and seven major U.S. health systems. This funding will accelerate the global rollout of Optain's advanced robotic retinal imaging, AI, and teleophthalmology platform.
2025-09
Pulse 2.0
Optain Health: $26 Million Secured To Expand AI-Based Retinal Screening - Pulse 2.0
Optain Health secured $26 million in Series A funding to expand its AI-based retinal screening platform. The investment, led by Insight Partners and joined by seven major U.S. health systems, will be used for scaling enterprise deployments, entering new markets, and advancing Optain's AI capabilities.
2025-09
PR Newswire
Optain Health Acquires EyePACS to Expand Access to Next-Generation Retinal Imaging for Primary Care and Advance Oculomics - PR Newswire
Optain Health acquired EyePACS, the largest teleophthalmology network in the U.S., to expand access to next-generation retinal imaging for primary care. This acquisition aims to prevent avoidable blindness and improve systemic health through fast, accessible, and high-quality retinal imaging.
2025-11
Optain Health
DH100: Advanced AI Retinal Imaging Device - Optain Health
Optain was named to the 2024 New York Digital Health 100 (DH100), recognizing it as one of the most exciting and innovative startups in New York. This acknowledgment highlights Optain's commitment to improving patient care through novel technologies like oculomics and AI.
2024-10
Medical Device News by Guided Solutions
Optain is the first company to come out of Ascertain from Northwell Health and Aegis Ventures - Medical Device News by Guided Solutions
Optain launched as the first company from Ascertain, a collaboration between Northwell Health and Aegis Ventures, with a $12 million seed round. The company uses AI and retinal imaging for early disease identification and prevention, with its technology already approved and marketed internationally.
2023-05

Frequently Asked Questions

Optain Health utilizes advanced AI algorithms to analyze high-resolution retinal images captured by their portable robotic camera, Resolveu2122, for early detection of diabetic retinopathy, glaucoma, and age-related macular degeneration. This technology provides rapid, accurate risk assessments, enabling earlier intervention and improved patient outcomes.
Optain Health facilitates teleophthalmology by providing AI-powered analysis of retinal images and, in the U.S., rapid teleophthalmology grading, allowing specialists to review and diagnose cases efficiently. Their solutions, including the FDA-cleared Resolveu2122 camera, are designed for seamless integration with major EHR systems and existing clinic workflows, requiring minimal staff training.
Optain Health's oculomics platform extends beyond eye-specific conditions by analyzing retinal biomarkers associated with systemic health, including indicators for cardiovascular disease risk. This non-invasive approach provides physicians with valuable insights into a patient's overall health, potentially enabling earlier detection and management of systemic conditions.
Optain Health offers the Eyetelligence Assure AI software for eye disease screening and cardiovascular assessment, along with the Resolveu2122 portable robotic fundus camera. The Resolveu2122 camera is FDA-cleared, and their AI algorithms are regulatory-approved, with solutions adhering to stringent data privacy standards like HIPAA.
Optain Health offers flexible pricing models and comprehensive customer support, including rapid staff training and seamless integration. The company demonstrates strong stability, having recently closed a $26 million Series A funding round with investments from Insight Partners and seven major U.S. health systems, and acquired EyePACS, the largest U.S. teleophthalmology network.

Investors

Who's funded Optain Health.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.